Glaxo pays £230M for preclinical portfolio of small antibodies In the highest value deal yet seen for a preclinical pipeline, GlaxoSmithKline plc swooped on Domantis Ltd, paying £230 million cash for the six-year-old UK Medical Research Council spin out. 12 Dec 2006 News